TW202325851A - 用於治療劑遞送之組合物及方法 - Google Patents

用於治療劑遞送之組合物及方法 Download PDF

Info

Publication number
TW202325851A
TW202325851A TW111140482A TW111140482A TW202325851A TW 202325851 A TW202325851 A TW 202325851A TW 111140482 A TW111140482 A TW 111140482A TW 111140482 A TW111140482 A TW 111140482A TW 202325851 A TW202325851 A TW 202325851A
Authority
TW
Taiwan
Prior art keywords
retroviral vector
interleukin
recombinant retroviral
polynucleotide sequence
individual
Prior art date
Application number
TW111140482A
Other languages
English (en)
Chinese (zh)
Inventor
布里列 鐘
瑟西利亞 羅
羅伯特 Ｇ 強森
Original Assignee
美商吉恩維沃公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商吉恩維沃公司 filed Critical 美商吉恩維沃公司
Publication of TW202325851A publication Critical patent/TW202325851A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111140482A 2021-10-25 2022-10-25 用於治療劑遞送之組合物及方法 TW202325851A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163271674P 2021-10-25 2021-10-25
US63/271,674 2021-10-25
US202263413165P 2022-10-04 2022-10-04
US63/413,165 2022-10-04

Publications (1)

Publication Number Publication Date
TW202325851A true TW202325851A (zh) 2023-07-01

Family

ID=86158435

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111140482A TW202325851A (zh) 2021-10-25 2022-10-25 用於治療劑遞送之組合物及方法

Country Status (8)

Country Link
US (2) US12234475B2 (enExample)
EP (1) EP4423287A4 (enExample)
JP (1) JP2024540002A (enExample)
KR (1) KR20240099339A (enExample)
AU (1) AU2022375623A1 (enExample)
CA (1) CA3235894A1 (enExample)
TW (1) TW202325851A (enExample)
WO (1) WO2023076177A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240099339A (ko) 2021-10-25 2024-06-28 젠비보, 인크. 치료제 전달을 위한 조성물 및 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651443A1 (de) 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
EP1914304A1 (en) 1998-10-14 2008-04-23 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US6743631B1 (en) 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
US6490476B1 (en) 1999-10-14 2002-12-03 Cti Pet Systems, Inc. Combined PET and X-ray CT tomograph and method for using same
US6825033B2 (en) 2000-03-02 2004-11-30 University Of Southern California Mutated cyclin G1 protein
US20010046491A1 (en) 2000-03-23 2001-11-29 Valerie Kristoffer C. Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug
US20050130132A1 (en) 2002-09-06 2005-06-16 Day Craig H. Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2004041844A2 (en) 2002-10-30 2004-05-21 Rigel Pharmaceuticals, Inc. Cell cycle targets and peptides
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US7815902B2 (en) 2003-07-09 2010-10-19 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
CN1871034B (zh) 2003-07-09 2011-07-06 亨利福特保健系统公司 用新型腺病毒治疗癌症的方法和组合物
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
CA2643102A1 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California A method for noninvasively and quantitatively monitoring therapeutic and diagnostic transgene expression induced by ex vivo and in vivo gene targeting in organs, tissues and cells
WO2008140961A2 (en) 2007-05-08 2008-11-20 The Government Of The U.S.A, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus pseudoviruses for detection and therapy of tumors
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
WO2009070636A2 (en) 2007-11-27 2009-06-04 Stanford University Engineered cells, imaging reporter gene/probe systems, and methods of imaging
US20090176260A1 (en) 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
KR101032871B1 (ko) 2009-07-10 2011-05-06 주식회사 바이오드 비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제
CN103339262A (zh) 2010-10-28 2013-10-02 弗吉尼亚联邦大学 具有治疗作用的癌症成像：治疗诊断学
US9636381B2 (en) 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
JP2016524590A (ja) 2013-03-14 2016-08-18 エペイウス バイオテクノロジーズ コーポレイション 遺伝子療法適用のためのチミジンキナーゼ診断アッセイ
AU2016317936A1 (en) * 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
WO2018150345A1 (en) * 2017-02-16 2018-08-23 De Vita Bio Life Sciences An expression vector
AU2018231190B2 (en) * 2017-03-08 2023-05-25 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
KR102702230B1 (ko) 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
ES3052818T3 (en) 2018-02-09 2026-01-14 Us Health Tethered interleukin-15 and interleukin-21
AU2020291946B2 (en) * 2019-06-14 2026-08-06 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
KR20240099339A (ko) 2021-10-25 2024-06-28 젠비보, 인크. 치료제 전달을 위한 조성물 및 방법

Also Published As

Publication number Publication date
JP2024540002A (ja) 2024-10-31
EP4423287A4 (en) 2025-10-22
CA3235894A1 (en) 2023-05-04
US20230265457A1 (en) 2023-08-24
WO2023076177A2 (en) 2023-05-04
AU2022375623A1 (en) 2024-05-02
US20250115930A1 (en) 2025-04-10
KR20240099339A (ko) 2024-06-28
US12234475B2 (en) 2025-02-25
WO2023076177A3 (en) 2023-08-24
EP4423287A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
ES2986097T3 (es) Proteínas de fusión de interleucina-2/receptor alfa de interleucina-2 y métodos de uso
JP7246343B2 (ja) 改善されたチミジンキナーゼ遺伝子
US11103555B2 (en) Compositions and methods for reducing tumor cell growth at a site of solid tumor excision
US12350327B2 (en) Compositions and methods for therapeutic or vaccine delivery
CN118451096A (zh) 异二聚体fc细胞因子及其用途
JP2026053539A (ja) Ｉｃｄ ｓｔａｔシグナル伝達が改変されたｃｄ１２２
US20250115930A1 (en) Compositions and methods for therapeutic delivery
TW202233661A (zh) 多功能及多價介白素-TGF-β受體融合多肽
CN118556129A (zh) 用于治疗剂递送的组合物和方法
JP2024509084A (ja) 核酸ベクター及び使用方法
CN118451188A (zh) 用于治疗剂或疫苗递送的组合物及方法
AU717974B2 (en) Transduced human hematopoietic stem cells
WO2024226784A2 (en) Compositions and methods for therapeutic or vaccine delivery
CN116917334A (zh) 一种具有抗癌活性的多结构域融合蛋白
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
WO2026077330A1 (zh) 一种增强肿瘤杀伤能力的工程化细胞及其应用